PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.44%
Revenue growth at 50-75% of 3391.T's 11.31%. Martin Whitman would worry about competitiveness or product relevance.
10.34%
Gross profit growth 1.25-1.5x 3391.T's 7.58%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
32.32%
EBIT growth 75-90% of 3391.T's 42.29%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
35.65%
Operating income growth similar to 3391.T's 36.97%. Walter Schloss would assume both share comparable operational structures.
36.95%
Net income growth comparable to 3391.T's 38.89%. Walter Schloss might see both following similar market or cost trajectories.
-31.52%
Negative EPS growth while 3391.T is at 38.78%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-31.52%
Negative diluted EPS growth while 3391.T is at 38.38%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
100.00%
Share count expansion well above 3391.T's 0.16%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
100.00%
Diluted share count expanding well above 3391.T's 0.46%. Michael Burry would fear significant dilution to existing owners' stakes.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.06%
Negative 10Y revenue/share CAGR while 3391.T stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-9.06%
Negative 5Y CAGR while 3391.T stands at 0.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-21.15%
Negative 3Y CAGR while 3391.T stands at 20.62%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Negative 10Y OCF/share CAGR while 3391.T stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-100.00%
Negative 5Y OCF/share CAGR while 3391.T is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-100.00%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
15.25%
10Y net income/share CAGR of 15.25% while 3391.T is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
15.25%
Net income/share CAGR of 15.25% while 3391.T is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
6.59%
Below 50% of 3391.T's 67.42%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.61%
Negative 3Y equity/share growth while 3391.T is at 43.06%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-100.00%
Cut dividends over 10 years while 3391.T stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-100.00%
Negative 5Y dividend/share CAGR while 3391.T stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-99.47%
Firm’s AR is declining while 3391.T shows 3.83%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.66%
Inventory is declining while 3391.T stands at 3.46%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.83%
Asset growth at 75-90% of 3391.T's 2.29%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
-47.19%
We have a declining book value while 3391.T shows 2.28%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-76.30%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
52.94%
SG&A growth well above 3391.T's 0.76%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.